ClinConnect ClinConnect Logo
Search / Trial NCT07151222

Role of Red Blood Cells in Cardiovascular Disease

Launched by KAROLINSKA INSTITUTET ·

Trial Information

Current as of September 12, 2025

Recruiting

Keywords

Red Blood Cells Nitric Oxide Diabetes

ClinConnect Summary

This clinical trial is studying how red blood cells (the cells that carry oxygen in your blood) affect heart health, especially in people with type 2 diabetes. Researchers have found that red blood cells normally help protect the heart during low oxygen conditions, like during a heart attack, by sending important chemical signals. However, in people with type 2 diabetes, these red blood cells don’t work properly and may cause damage to the heart and blood vessels. The study aims to better understand these processes and explore new ways to treat heart problems by targeting the way red blood cells function.

People who have had a heart attack, have type 2 diabetes, or are healthy volunteers may be eligible to take part. Participants will have their blood collected to study the red blood cells in the lab, and researchers will look at how these cells affect heart and blood vessel function. This study is currently recruiting, and anyone interested can ask their doctor if joining might be right for them. The findings could lead to new treatments that help protect the heart, especially for people with diabetes.

Gender

ALL

Eligibility criteria

About Karolinska Institutet

Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.

Locations

Patients applied

0 patients applied

Trial Officials

John Pernow, MD

Principal Investigator

Karolinska Institutet

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported